iRhythm Holdings, Inc.
NMS: IRTCLive Quote
📈 ZcoreAI Score
Our AI model analyzes iRhythm Holdings, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get IRTC Z-Score →About iRhythm Holdings, Inc.
Healthcare
Medical Devices
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
📊 Fundamental Analysis
iRhythm Holdings, Inc. demonstrates a profit margin of -6.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported 27.1% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is -36.6%, which indicates that capital utilization is currently under pressure.
At a current price of $115.24, IRTC currently trades near the bottom of its 52-week range (16%), indicating potential value or weakness (Range: $97.16 - $212.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$3.72B
Trailing P/E
--
Forward P/E
137.79
Beta (5Y)
1.18
52W High
$212.00
52W Low
$97.16
Avg Volume
656K
Day High
Day Low